FDA Taps Tech Venture to Help Solve Vaping's Youth Access Crisis

LOS ANGELES, CA – February 04, 2026 – The U.S. Food and Drug Administration has extended a rare invitation to a technology startup, signaling a potential shift in its strategy to combat underage vaping. IKE Tech LLC, a joint venture backed by vaping technology firm Ispire Technology Inc. (NASDAQ: ISPR), will participate in an exclusive, invitation-only FDA roundtable on February 10 to discuss the future of product regulation for electronic nicotine delivery systems (ENDS).

The invitation places IKE Tech among a select group of just 30 companies nationwide chosen to provide direct feedback on the agency’s beleaguered Premarket Tobacco Product Application (PMTA) process. For an industry struggling with regulatory hurdles and a persistent youth access problem, the FDA’s focus on a company specializing in high-tech age-gating suggests that technological solutions are moving from the fringe to the forefront of the conversation.

A Seat at the Regulatory Table

Participation in the FDA’s roundtable is a significant development for any company in the ENDS space. The PMTA process, the sole pathway to legally market new vaping products, is notoriously complex and expensive. Manufacturers must provide extensive scientific evidence that their product is “appropriate for the protection of public health.” The financial and scientific burden has been immense, with application costs sometimes soaring towards $100 million and an exceedingly low authorization rate; as of early 2023, the FDA had authorized only 23 of the more than 26 million product applications submitted.

IKE Tech is slated to join the “Manufacturing Controls” panel, one of five discussions intended to explore real-world challenges and potential improvements to the regulatory framework. The feedback gathered is expected to inform future FDA guidance, potentially streamlining the path to market for companies that can demonstrate robust controls, particularly against youth access.

“This invitation reflects growing recognition by regulators that technology, particularly point-of-use age-gating, is a critical component of a responsible ENDS ecosystem,” said Michael Wang, Co-CEO of Ispire, in a statement. He emphasized the opportunity to advance public health objectives, noting, “The FDA's engagement reinforces that age-gating is no longer a peripheral concept — it is central to the future of regulation.”

The Technology at the Center of the Dialogue

Unlike traditional age-verification methods that occur only at the retail counter and are often easily circumvented, IKE Tech’s solution is designed to be integrated directly into the vaping device itself. The company is developing a blockchain-enabled, Bluetooth-based component that verifies a user's age at the moment of use.

This “System-on-a-Chip” technology requires the user to authenticate their identity—using methods that can include mobile and biometric verification—before the device will function. The goal is to create a digital lock that prevents a legally purchased device from being used by a minor. The system reportedly achieved 100% effectiveness in preventing underage access during clinical trials.

Significantly, IKE Tech’s technology is the subject of the first-ever “component PMTA” submission for an interoperable age-verification system. If authorized by the FDA, this would allow other ENDS manufacturers to incorporate IKE’s pre-vetted technology into their own products and PMTA submissions, potentially creating a new industry standard for compliance and dramatically simplifying a key part of the application process for other companies.

“We look forward to sharing how technical controls can offer a more effective pathway for adult products while ensuring the highest standards of youth protection,” Wang added.

Ispire's Strategic Bet on Compliance

The move puts a spotlight on Ispire Technology's broader strategy. The company, which develops and markets its own e-cigarette and cannabis vaping products, has recently navigated a strategic pivot. After reporting a revenue decline in its latest fiscal year, Ispire has emphasized its focus on breakthrough technologies and quality partnerships for sustainable growth. The investment in the IKE Tech joint venture, formed in 2024 with Berify and Chemular Inc., appears to be the cornerstone of this long-term vision.

By backing a company that could potentially define the next generation of regulatory compliance, Ispire is positioning itself not just as a product manufacturer, but as a key player in the underlying technological infrastructure of the entire industry. Success for IKE Tech could translate into a significant competitive advantage for Ispire, transforming a compliance headache into a revenue-generating solution.

“Our strategic investment in IKE Tech positions Ispire at the center of regulatory dialogue as the FDA evaluates how innovation can strengthen compliance, protect youth and support lawful market pathways for adult products,” Wang’s statement concluded, underscoring the dual goals of public health alignment and strategic market positioning.

Beyond Vaping: The Rise of Point-of-Use Identity

The implications of IKE Tech’s platform extend far beyond the vaping industry. The company’s mission to build “the identity layer for the physical world” speaks to a broader trend across numerous regulated sectors. The same fundamental challenge—ensuring a product is used only by its intended, authorized user—exists for industries like alcohol, cannabis, and even firearms.

As more physical objects become connected to the internet, the concept of point-of-use verification is gaining traction. Regulatory bodies beyond the FDA, including the Federal Trade Commission, are exploring how age-assurance technologies can enforce rules like the Children's Online Privacy Protection Act (COPPA). IKE Tech's use of blockchain for secure, decentralized identity verification, combined with biometrics and secure Bluetooth communication, places it within this larger movement toward embedding trust and control into everyday objects.

The upcoming FDA roundtable will serve as a crucial test, not only for IKE Tech’s vision but for the agency's willingness to embrace technological innovation as a core component of its public health mission. The outcome of these discussions could set a precedent for how regulated products are designed, sold, and used for years to come. As regulators and industries grapple with these questions, the performance of technologies like IKE's will be scrutinized not just for their ability to lock a device, but for their power to unlock a new paradigm of responsible commerce.